BioSpace News Archive

Earnings

Sarepta Previews Q4 Findings, Touts Elevidys Earnings Beat

Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter of 2024, reflecting the biotech’s “world-class” execution, according to BMO Capital Markets analysts.

January 14, 2025

·

2 min read

·

Tristan Manalac

A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.

Cancer

Where Keytruda Failed, Regeneron Touts Phase III Skin Cancer Win for Libtayo

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which exceeded the consensus by a modest 1% and are bogged down by the slow conversion of patients to the high-dose formulation.

January 14, 2025

·

2 min read

·

Tristan Manalac

Drug Development

Could New Leqembi Formulations Boost Lagging Sales in Alzheimer’s?

The FDA accepted Biogen and Eisai’s BLA for a subcutaneous administration of the anti-amyloid antibody Monday as the partners await the regulator’s decision on a new intravenous regimen following an underwhelming launch riddled with coverage and accessibility barriers.

January 14, 2025

·

1 min read

·

Kate Goodwin

Trendy halftone collage. Concept of contracting, negotiation, contracting, favorable terms. Trendy modern retro illustration on business theme. Concept of teamwork. Vector illustration

Gene therapy

Regenxbio Jumps on Potential $800M Rare Disease Deal With Nippon Shinyaku

In exchange for its investigational gene therapies, Regenxbio will receive $110 million upfront and up to $700 million in milestones. After hitting an all-time low of $6.95 at close of business yesterday, the stock surged on the news by nearly 20% before markets opened Tuesday.

January 14, 2025

·

2 min read

·

Tristan Manalac

Earnings

Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.

January 14, 2025

·

2 min read

·

Dan Samorodnitsky

The Gariep Dam overflowing. The dam is the largest in South Africa. It is in the Orange River on the border between the Free State and Eastern Cape Provinces. Monochrome

Deals

Biopharma Deals Start Flowing at JPM25—With One Dwarfing Last Year’s Activity

J.P. Morgan kicked off with a flurry of deals, with Eli Lilly, GSK and Gilead all announcing deals potentially worth more than $1 billion while J&J committed $14.6 billion to buy Intra-Cellular. These moves have reinvigorated sentiment across the biopharma industry.

January 14, 2025

·

3 min read

·

Annalee Armstrong

Pictured: A sign on a J.P. Morgan building in Hong Kong/iStock, danielvfung

Pipeline

JPM25 Day One: Pfizer, BioNTech, Moderna and More Present Pipeline Updates

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine pipelines.

January 14, 2025

·

3 min read

·

Dan Samorodnitsky

Weigh scales on pink background, top view with space for text. Overweight concept

GLP-1

Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera Therapeutics outlining their plans in the space moving forward.

January 14, 2025

·

2 min read

·

Tristan Manalac

Press Releases

BostonGene Evaluates Novel Therapies and Immune System Profiling as a Marker of Response in Patients with Gastrointestinal Cancers

January 14, 2025

·

5 min read

Press Releases

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

January 14, 2025

·

7 min read